Bupropion

is prescribed to treat:

• Depression, seasonal affective disorder, and smoking cessation • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Bupropion (Wellbutrin, Zyban) is an atypical antidepressant used for major depressive disorder, seasonal affective disorder, and smoking cessation in nicotine dependence. It works through a mechanism entirely different from the SSRIs, and that difference — not superior efficacy — is what determines when it is the right choice.

Mechanism of Action

Bupropion inhibits reuptake of norepinephrine and dopamine, with no meaningful serotonergic activity. It is the only widely used antidepressant with this profile, and essentially every distinctive feature follows from it.

Because it does not act on serotonin, bupropion does not cause the sexual dysfunction that affects a substantial minority of SSRI-treated patients and is the most common unspoken reason they stop. It does not cause the weight gain associated with several other antidepressants and is generally weight-neutral or modestly weight-reducing. It tends to be activating rather than sedating.

Those same properties define its limits. Bupropion is not effective for anxiety disorders and can worsen anxiety, particularly early — so it is a poor choice for a patient whose depression is dominated by anxious agitation, and a good one where fatigue, low motivation, and hypersomnia predominate.

Its dopaminergic activity underlies its role in smoking cessation, where it reduces craving and withdrawal independently of its antidepressant effect. It also lowers the seizure threshold in a dose-dependent way, which is the basis of its main contraindications.

Clinical Use

Bupropion is a reasonable first-line antidepressant and a common second choice after an SSRI, either as a switch or as an augmentation. Adding bupropion to an SSRI is one of the better-established strategies for partial response and has the useful side effect of counteracting SSRI-induced sexual dysfunction — a combination worth knowing about, since patients frequently stop an otherwise effective SSRI for exactly that reason rather than reporting it.

For smoking cessation it is started one to two weeks before the quit date, so levels are established before the attempt, and continued for several months afterwards. It can be combined with nicotine replacement. Varenicline is generally more effective, but bupropion is a good option where varenicline is not tolerated or where depression is also being treated.

The activating profile means morning dosing is preferable, and adding a late dose can cause insomnia. Dry mouth, headache, and jitteriness are common early and usually settle. The smoking cessation article covers how the options compare, and our psychiatric team manages depression treatment alongside therapy referral.

Seizure Risk and Contraindications

Bupropion lowers the seizure threshold, and the risk is dose-dependent and formulation-dependent. The immediate-release form carries higher risk than the sustained- and extended-release preparations, which is why the latter are used almost exclusively now.

It is contraindicated in seizure disorders, in current or prior anorexia nervosa or bulimia — eating disorders raise seizure risk substantially through electrolyte disturbance — and in patients undergoing abrupt discontinuation of alcohol or benzodiazepines, since withdrawal itself lowers the threshold.

Risk factors that warrant caution include head injury, CNS tumour, concurrent medications that lower the seizure threshold, and conditions predisposing to electrolyte disturbance. Adhering to maximum recommended doses and avoiding immediate-release formulations keeps absolute risk low in patients without these factors. The MedlinePlus bupropion entry covers prescribing detail.

One further practical point: bupropion is a potent CYP2D6 inhibitor. It raises levels of substrates including metoprolol and reduces conversion of tamoxifen to its active metabolite, which matters in breast cancer patients.

Monitoring and Follow-Up

Follow up within one to two weeks of starting, particularly in younger patients, then at four to six weeks to assess response. Standardised measures such as the PHQ-9 make partial response visible.

Blood pressure warrants monitoring, since bupropion raises it modestly through its noradrenergic effect — relevant in patients with existing hypertension, and more so when combined with nicotine replacement.

No routine laboratory monitoring is required. Assess sleep, since insomnia is common and usually manageable by moving the dose earlier, and assess anxiety, which can worsen. An adequate trial means an adequate dose for at least four to six weeks. The National Institute of Mental Health provides patient-level background on what treatment should look like.

Bupropion causes less discontinuation syndrome than short-half-life SSRIs, but tapering remains preferable to abrupt cessation.

Naltrexone-bupropion is marketed as a weight-management combination, and patients sometimes arrive already taking it without connecting it to the antidepressant they are also prescribed. Doubling up on bupropion this way raises seizure risk in exactly the dose-dependent manner the contraindications are built around, and the combination product's brand name gives no hint that bupropion is in it. Checking the full ingredient list of any weight-loss or smoking-cessation product a patient is taking is worth the moment it costs.

Special Populations

Antidepressants carry a boxed warning about increased suicidal thinking in patients under 25 during early treatment, which calls for closer follow-up rather than avoidance — untreated depression carries substantial risk of its own.

In older adults, bupropion is often well tolerated and its lack of anticholinergic activity, sedation, and orthostatic hypotension is a genuine advantage over many alternatives; blood pressure and seizure risk factors warrant attention. Hepatic and renal impairment both slow clearance and require dose reduction. In pregnancy it is used when indicated, and it has a role where smoking cessation is also a goal. It is contraindicated within two weeks of an MAO inhibitor.

When to Contact Your Doctor

Seek emergency care for a seizure. Report new or worsening anxiety, agitation, or insomnia — these are common early and usually manageable, but they should not simply be endured. Report new or worsening thoughts of self-harm, or a switch into unusually elevated mood or reduced need for sleep.

Report rising blood pressure readings. Any rash, particularly a blistering or peeling rash or one with fever, needs immediate evaluation. If you are taking bupropion for smoking cessation and have resumed smoking, that is worth discussing rather than stopping the medication — a second attempt with adjusted support is often successful.

To review your antidepressant, discuss sexual side effects on a current medication, or plan a quit attempt, contact us or schedule a visit.